359 related articles for article (PubMed ID: 20651070)
21. Lenalidomide mode of action: linking bench and clinical findings.
Davies F; Baz R
Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
[TBL] [Abstract][Full Text] [Related]
22. Novel immunomodulatory compounds in multiple myeloma.
Saini N; Mahindra A
Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
Anderson KC; Prince HM
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S1-2. PubMed ID: 16344096
[No Abstract] [Full Text] [Related]
24. Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.
Bam R; Khan S; Ling W; Randal SS; Li X; Barlogie B; Edmondson R; Yaccoby S
BMC Cancer; 2015 Nov; 15():864. PubMed ID: 26545722
[TBL] [Abstract][Full Text] [Related]
25. Immunomodulatory compounds (IMiDs) in the treatment of multiple myeloma.
Srkalovic G; Hussein M
Bosn J Basic Med Sci; 2009 Oct; 9 Suppl 1(Suppl 1):S3-S10. PubMed ID: 19912117
[TBL] [Abstract][Full Text] [Related]
26. Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.
Vo MC; Yang S; Jung SH; Chu TH; Lee HJ; Lakshmi TJ; Park HS; Kim HJ; Lee JJ
Front Immunol; 2018; 9():1798. PubMed ID: 30123221
[TBL] [Abstract][Full Text] [Related]
27. Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells.
Endo S; Amano M; Nishimura N; Ueno N; Ueno S; Yuki H; Fujiwara S; Wada N; Hirata S; Hata H; Mitsuya H; Okuno Y
Biochem Biophys Res Commun; 2016 Jan; 469(2):236-42. PubMed ID: 26657848
[TBL] [Abstract][Full Text] [Related]
28. Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.
Jungkunz-Stier I; Zekl M; Stühmer T; Einsele H; Seggewiss-Bernhardt R
Leuk Lymphoma; 2014 Jan; 55(1):168-76. PubMed ID: 23573828
[TBL] [Abstract][Full Text] [Related]
29. Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML).
Zeidner JF; Foster MC
Curr Drug Targets; 2017; 18(3):304-314. PubMed ID: 25738295
[TBL] [Abstract][Full Text] [Related]
30. Immunomodulatory drugs as a therapy for multiple myeloma.
De Raeve H; Vanderkerken K
Curr Pharm Biotechnol; 2006 Dec; 7(6):415-21. PubMed ID: 17168657
[TBL] [Abstract][Full Text] [Related]
31. Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma.
Maïga S; Gomez-Bougie P; Bonnaud S; Gratas C; Moreau P; Le Gouill S; Pellat-Deceunynck C; Amiot M
Br J Cancer; 2013 May; 108(9):1801-6. PubMed ID: 23632478
[TBL] [Abstract][Full Text] [Related]
32. Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma.
Mitsiades CS; Chen-Kiang S
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S5-13. PubMed ID: 23806982
[TBL] [Abstract][Full Text] [Related]
33. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.
Cho SF; Lin L; Xing L; Li Y; Wen K; Yu T; Hsieh PA; Munshi N; Wahl J; Matthes K; Friedrich M; Arvedson T; Anderson KC; Tai YT
Blood Adv; 2020 Sep; 4(17):4195-4207. PubMed ID: 32898244
[TBL] [Abstract][Full Text] [Related]
34. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.
Castelli R; Cannavò A; Conforti F; Grava G; Cortelezzi A
Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):740-53. PubMed ID: 22401643
[TBL] [Abstract][Full Text] [Related]
35. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.
Gandhi AK; Kang J; Capone L; Parton A; Wu L; Zhang LH; Mendy D; Lopez-Girona A; Tran T; Sapinoso L; Fang W; Xu S; Hampton G; Bartlett JB; Schafer P
Curr Cancer Drug Targets; 2010 Mar; 10(2):155-67. PubMed ID: 20088798
[TBL] [Abstract][Full Text] [Related]
36. [Immunomodulator drugs for the treatment of multiple myeloma].
Fernández-Lázaro D; Fernández-Lázaro CI; Caballero García A; Córdova Martínez A
Rev Med Chil; 2018 Dec; 146(12):1444-1451. PubMed ID: 30848748
[TBL] [Abstract][Full Text] [Related]
37. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.
Schafer PH; Gandhi AK; Loveland MA; Chen RS; Man HW; Schnetkamp PP; Wolbring G; Govinda S; Corral LG; Payvandi F; Muller GW; Stirling DI
J Pharmacol Exp Ther; 2003 Jun; 305(3):1222-32. PubMed ID: 12649301
[TBL] [Abstract][Full Text] [Related]
38. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
Bolomsky A; Hübl W; Spada S; Müldür E; Schlangen K; Heintel D; Rocci A; Weißmann A; Fritz V; Willheim M; Zojer N; Palumbo A; Ludwig H
Am J Hematol; 2017 Mar; 92(3):269-278. PubMed ID: 28052520
[TBL] [Abstract][Full Text] [Related]
39. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.
Paiva B; Mateos MV; Sanchez-Abarca LI; Puig N; Vidriales MB; López-Corral L; Corchete LA; Hernandez MT; Bargay J; de Arriba F; de la Rubia J; Teruel AI; Giraldo P; Rosiñol L; Prosper F; Oriol A; Hernández J; Esteves G; Lahuerta JJ; Bladé J; Perez-Simon JA; San Miguel JF;
Blood; 2016 Mar; 127(9):1151-62. PubMed ID: 26668134
[TBL] [Abstract][Full Text] [Related]
40. Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression.
Giuliani M; Janji B; Berchem G
Oncotarget; 2017 Apr; 8(14):24031-24044. PubMed ID: 28199990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]